2020
Clinical implications of oxidative stress in schizophrenia: Acute relapse and chronic stable phase
Chien Y, Hwu H, Hwang T, Hsieh M, Liu C, Lin-Shiau S, Liu C. Clinical implications of oxidative stress in schizophrenia: Acute relapse and chronic stable phase. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2020, 99: 109868. PMID: 31954755, DOI: 10.1016/j.pnpbp.2020.109868.Peer-Reviewed Original ResearchConceptsChronic stable schizophreniaNon-psychiatric controlsDisorganized symptomsChronic stable patientsStable schizophreniaWeeks of antipsychotic treatmentStages of schizophreniaAcute relapseClinical implicationsAntipsychotic treatmentNegative symptomsSchizophreniaStable patientsOxidative stressPlatelet superoxide dismutasePlatelet oxidative stressTreatment responseNitric oxideLipid peroxidationLevels of nitric oxideSymptomsSuperoxide dismutaseTreatment effectsRelapsed patientsRelapse
2015
Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer
Shi S, Ji S, Qin Y, Xu J, Zhang B, Xu W, Liu J, Long J, Liu C, Liu L, Ni Q, Yu X. Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer. Cancer Letters 2015, 360: 227-233. PMID: 25687883, DOI: 10.1016/j.canlet.2015.02.014.Peer-Reviewed Original ResearchConceptsMetabolic tumor burdenMetabolic tumor volumeSerum tumor markersTumor burdenTumor markersPancreatic cancerAbnormal expressions of TP53Abnormal expressionMonitoring treatment responsePancreatic cancer patientsProgression of pancreatic cancerExpression of TP53Tumor volumeCA19-9SMAD4/DPC4 geneTreatment responseCancer patientsDisease progressionPET/CTPredictive significanceSurvival rateLethal diseasePatientsCancerSerum
2014
Adjuvant valproate therapy for patients with suspected mixed-depressive features
Liu C. Adjuvant valproate therapy for patients with suspected mixed-depressive features. Therapeutic Advances In Psychopharmacology 2014, 4: 143-148. PMID: 25083273, PMCID: PMC4104709, DOI: 10.1177/2045125314532868.Peer-Reviewed Original ResearchResistance to antidepressant therapyTolerability of mood stabilizersValproate therapyAdverse eventsRisk of suicideTreatment-emergent adverse eventsPsychiatric outpatientsAntidepressant therapyMood stabilizersBipolar disorderMood disordersTreated with valproateRetrospective observational studyReviewed medical recordsCourse of treatmentAggravation of symptomsStopping valproateTreatment responseAdjuvant therapyValproatePatient demographicsClinical entityClinical profileTreated patientsBipolar
2013
Aripiprazole for Drug-Naive or Antipsychotic-Short-Exposure Subjects With Ultra-High Risk State and First-Episode Psychosis
Liu C, Chien Y, Hsieh M, Hwang T, Hwu H, Liu C. Aripiprazole for Drug-Naive or Antipsychotic-Short-Exposure Subjects With Ultra-High Risk State and First-Episode Psychosis. Journal Of Clinical Psychopharmacology 2013, 33: 18-23. PMID: 23277261, DOI: 10.1097/jcp.0b013e31827cb017.Peer-Reviewed Original ResearchConceptsFirst-episode psychosisUltra-high riskFirst-episode psychosis patientsDrug-naiveUltra-high risk stateUltra-high-risk patientsLow-dose aripiprazoleNegative symptom scoresPositive symptom scoresFlexible dosing strategyState of psychosisTreatment responseAntipsychotic therapyDrug-naive populationSevere psychopathologyUHR patientsFirst-episodeAripiprazoleAdverse eventsSymptom scoresPsychosisRisk stateConcomitant medicationsTarget doseClinical improvement